JP2003528155A - Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法 - Google Patents

Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法

Info

Publication number
JP2003528155A
JP2003528155A JP2001570294A JP2001570294A JP2003528155A JP 2003528155 A JP2003528155 A JP 2003528155A JP 2001570294 A JP2001570294 A JP 2001570294A JP 2001570294 A JP2001570294 A JP 2001570294A JP 2003528155 A JP2003528155 A JP 2003528155A
Authority
JP
Japan
Prior art keywords
antibody
variant
treatment
fragment
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001570294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528155A5 (https=
Inventor
モーリス ジェイ． ウォリン，
ジョセフ ディー． ローゼンブラット，
Original Assignee
カイロン コーポレイション
ユニヴァーシティー オヴ ロチェスター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション, ユニヴァーシティー オヴ ロチェスター filed Critical カイロン コーポレイション
Publication of JP2003528155A publication Critical patent/JP2003528155A/ja
Publication of JP2003528155A5 publication Critical patent/JP2003528155A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001570294A 2000-03-24 2001-03-23 Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法 Pending JP2003528155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19204700P 2000-03-24 2000-03-24
US60/192,047 2000-03-24
PCT/US2001/009413 WO2001072333A1 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2

Publications (2)

Publication Number Publication Date
JP2003528155A true JP2003528155A (ja) 2003-09-24
JP2003528155A5 JP2003528155A5 (https=) 2008-04-17

Family

ID=22708018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570294A Pending JP2003528155A (ja) 2000-03-24 2001-03-23 Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法

Country Status (7)

Country Link
US (1) US20020009427A1 (https=)
EP (1) EP1267927A1 (https=)
JP (1) JP2003528155A (https=)
AU (1) AU2001247737A1 (https=)
CA (1) CA2404390A1 (https=)
IL (1) IL151906A0 (https=)
WO (1) WO2001072333A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
CA2396793A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
JP2005538034A (ja) * 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
KR101033196B1 (ko) * 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN1692127A (zh) * 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
AU2011202520C1 (en) * 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
AU2015205832A1 (en) * 2002-10-17 2015-08-13 Genmab A/S Human Monoclonal Antibodies Against CD20
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
JP2007536246A (ja) * 2004-05-05 2007-12-13 ジェネンテック・インコーポレーテッド 自己免疫疾患の予防法
EP1765400A2 (en) * 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
TW201422238A (zh) * 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
CN101027100A (zh) * 2004-07-22 2007-08-29 健泰科生物技术公司 治疗干燥综合征的方法
CA2580271A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
ZA200705459B (en) * 2005-01-13 2008-09-25 Genentech Inc Treatment method
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ATE460672T1 (de) * 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
JP2009502936A (ja) 2005-07-25 2009-01-29 トルビオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２０特異的結合分子の単一投与量
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP6049163B2 (ja) * 2008-07-21 2016-12-21 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 改善された治療上の特徴のための抗体の構造変異体
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
CN102050879B (zh) * 2009-10-30 2014-02-19 上海抗体药物国家工程研究中心有限公司 抗人cd20人源化抗体、其制备方法及用途
US20110145072A1 (en) * 2009-12-15 2011-06-16 Bradley John Christiansen System and Method for Producing And Displaying Content Representing A Brand Persona
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

Also Published As

Publication number Publication date
EP1267927A1 (en) 2003-01-02
CA2404390A1 (en) 2001-10-04
US20020009427A1 (en) 2002-01-24
WO2001072333A1 (en) 2001-10-04
IL151906A0 (en) 2003-04-10
AU2001247737A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
JP2003528155A (ja) Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法
US7306801B2 (en) Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
JP4494977B2 (ja) Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
JP2024127941A (ja) 抗ｂｃｍａ重鎖のみ抗体
CN102209556B (zh) 改良的抗cd19抗体
US20030185796A1 (en) Methods of therapy for non-hodgkin's lymphoma
JP2024084776A (ja) 抗ｂｃｍａ重鎖のみ抗体
NZ795790A (en) Anti-BCMA heavy chain-only antibodies
JPWO2001023432A1 (ja) ガングリオシドｇｄ３に対するヒト型相補性決定領域移植抗体およびガングリオシドｇｄ３に対する抗体の誘導体
CN115803057A (zh) 治疗多发性骨髓瘤的方法
JP2005538034A (ja) 非ホジキンリンパ腫の治療方法
KR20040086383A (ko) 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
JP2009120583A (ja) 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
KR20100113572A (ko) 항-ＥＤｂ 피브로넥틴 항체-ＩＬ-２ 융합 단백질과 Ｂ 세포, Ｂ 세포 전구체 및/또는 이의 암성 대응물에 결합하는 분자의 조합물
KR20090115895A (ko) Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
AU2020319899B2 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CN111133007A (zh) 与胞外酶结合的重链抗体
JP2011503039A (ja) 癌治療用医薬組成物
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
KR20210102917A (ko) 종양 질환을 치료하기 위한 il-15 단백질 복합체 연합 pd-l1 항체의 용도
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
JP7659546B2 (ja) 造血器がんの治療のための抗ｃｄ３０ ａｄｃ、抗ｐｄ－１、および化学療法剤の併用
KR20200066676A (ko) 항-cd30 항체 약물 콘주게이트 요법의 부작용을 감소시키는 방법
US20030235556A1 (en) Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
KR20240167457A (ko) 오드로넥스타맙을 사용한 사이토킨 방출 증후군의 완화를 위한 투여 용법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110902